Reviva Pharmaceuticals Inc Appoints Three New Board Members

SANTA CLARA, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals, Inc., (Reviva), a privately held drug discovery and development company, announced today that it has appointed life sciences industry experts, Brian G. Atwood, Sarvajna Dwivedi and Peder K. Jensen to its Board of Directors. "We are extremely pleased to welcome Mr. Atwood, Dr. Jensen and Dr. Dwivedi to the Board," said Laxminarayan Bhat, Founder, President and Chief Executive Officer of Reviva.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.